journal
MENU ▼
Read by QxMD icon Read
search

Hematological Oncology

journal
https://read.qxmd.com/read/31102421/combined-use-of-ddgp-and-imrt-has-a-good-effect-on-extranodal-natural-killer-t-cell-lymphoma-nasal-type
#1
LETTER
Yingjuan Zheng, Chunzhao Yang, Tiansong Liang, Daoke Yang, Zhangsuo Liu
No abstract text is available yet for this article.
May 18, 2019: Hematological Oncology
https://read.qxmd.com/read/31102420/decitabine-treatment-for-an-unusual-case-of-atypical-chronic-myeloid-leukemia-acml-with-a-concomitant-chronic-lymphocytic-leukemia-cll
#2
LETTER
R Cassin, V Mattiello, M Viltadi, D D'Aliberti, R Piazza, C Gambacorti-Passerini, U Gianelli, A Neri, A Cortelezzi, G Reda
Atypical chronic myeloid leukemia (aCML) is a rare hematological malignancy with dismal prognosis, usually being reported as isolated disease or in association with other myeloid neoplasms. Treatment strategies used for MDS and MPN, as hypomethylating agents (HMA) or kinase inhibitors, may be considered although experience is limited. We biologically studied an old patient affected by aCML unusually mutated for both SETBP1 and CSF3R, with concomitant chronic lymphocytic leukemia (CLL). Decitabine (DCA) therapy carried complete response after fourth cycle and was complicated by hematological toxicities and infections mainly due to the old age and the CLL-related immune deficit...
May 18, 2019: Hematological Oncology
https://read.qxmd.com/read/31102419/serum-exosomal-micrornas-as-novel-biomarkers-for-multiple-myeloma
#3
Zhi-Yao Zhang, Yanchen Li, Chuan-Ying Geng, Huixing Zhou, Wen Gao, Wen-Ming Chen
Accumulating studies have focused on circulating microRNAs, which might be potential biomarkers for different malignancies. The aim of this study was to investigate the potential of serum exosomal microRNAs to be novel serum biomarkers for smouldering myeloma or even multiple myeloma. The levels of serum exosomal microRNAs and serum circulating microRNAs were measured in healthy individuals and patients with smouldering myeloma (SMM) (n=20) or multiple myeloma (n=20). Serum exosomal microRNAs and serum circulating microRNAs were extracted from serum, and the expression levels of selected microRNAs were quantified by real-time PCR...
May 18, 2019: Hematological Oncology
https://read.qxmd.com/read/31074879/plasma-soluble-programmed-death-ligand-1-levels-predict-clinical-response-in-peripheral-t-cell-lymphomas
#4
Xuhan Zhang, Lu Liu, Shiyong Zhou, Kuo Zhao, Zheng Song, Ge Hu, Tingting Zhang, Yang Li, Lihua Qiu, Lanfang Li, Zhengzi Qian, Bin Meng, Yi Pan, Xiubao Ren, Xianhuo Wang, Huilai Zhang, Kai Fu
Immune checkpoints, including PD-1/PD-L1, play an important role in immunosuppression in various malignancies. Elevated levels of soluble programmed death-ligand1 (sPD-L1) are associated with worse prognosis in multiple myeloma and diffuse large B cell lymphoma. Herein, the purpose of this study is to investigate the relationships between plasma sPD-L1 levels and clinical response in peripheral T-cell lymphomas (PTCLs) patients. A total of 37 PTCLs patients and 20 healthy volunteers were enrolled. Peripheral blood from patients was collected prior to systemic therapy...
May 10, 2019: Hematological Oncology
https://read.qxmd.com/read/31050810/treatment-of-philadelphia-negative-myeloproliferative-neoplasms-in-accelerated-blastic-phase-with-azacytidine-clinical-results-and-identification-of-prognostic-factors
#5
Alessandro Andriani, Elena Elli, Giulio Trapè, Nicoletta Villivà, Luana Fianchi, Ambra Di Veroli, Pasquale Niscola, Antonia Centra, Barbara Anaclerico, Guido Montanaro, Vincenza Martini, Andrea Aroldi, Ida Carmosino, Maria Teresa Voso, Massimo Breccia, Marco Montanaro, Roberto Foà, Roberto Latagliata
There have been some reports on a possible role of azacytidine (AZA) in the treatment of accelerated/blastic phase evolved from Philadelphia-negative myeloproliferative neoplasms (MPN-AP/BP), but results are conflicting. In this study, we analyzed a cohort of 39 patients with MPN-AP/BP treated frontline with AZA at the standard dosage (75 mg/m2 ). Median time from diagnosis to AP/BP evolution was 92.3 months (IR 29.9 - 180.1). All patients were evaluable for hematologic response: 2 patients (5.2%) died early after AZA initiation, 13 patients (33...
May 3, 2019: Hematological Oncology
https://read.qxmd.com/read/31026087/hodgkin-lymphoma-transformation-of-chronic-lymphocytic-leukemia-a-real-life-data-from-the-polish-lymphoma-research-group
#6
Joanna Drozd-Sokołowska, Jan Maciej Zaucha, Tomasz Żółtak, Krzysztof Jamroziak, Olga Grzybowska-Izydorczyk, Magdalena Witkowska, Anna Waszczuk-Gajda, Maciej Kaźmierczak, Andrzej Szczepaniak, Edyta Subocz, Wanda Knopińska-Posłuszny, Jadwiga Hołojda, Anna Kopińska, Iwona Hus, Justyna Rybka, Dariusz Wołowiec, Jacek Kwiatkowski, Kazimierz Hałaburda, Piotr Smolewski, Sebastian Giebel, Wiesław Wiktor-Jędrzejczak
Richter transformation (RT) of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) to Hodgkin lymphoma (HL) is a rare and unexpected event in the course of the disease and data on this phenomenon is still limited. To better understand the clinical and histological characteristics and the outcomes of HL variant of RT (HvRT) the Polish Lymphoma Research Group performed a nationwide survey which identified 22 patients with histologically proven HvRS diagnosed between 2002 and 2016. There were 16 (73%) males...
April 26, 2019: Hematological Oncology
https://read.qxmd.com/read/31017684/risk-of-infectious-complications-in-patients-with-chronic-lymphocytic-leukemia-in-the-era-of-bcr-inhibitors-a-retrospective-single-institution-experience
#7
LETTER
Francesco Autore, Idanna Innocenti, Francesca Morelli, Federica Sorà, Andrea Corbingi, Luana Fianchi, Marianna Criscuolo, Livio Pagano, Simona Sica, Luca Laurenti
No abstract text is available yet for this article.
April 24, 2019: Hematological Oncology
https://read.qxmd.com/read/31013548/emerging-translational-science-discoveries-clonal-approaches-and-treatment-trends-in-chronic-myeloproliferative-neoplasms
#8
Tariq I Mughal, Naveen Pemmaraju, Jerald P Radich, Michael W Deininger, Nicole Kucine, Jean-Jacques Kiladjian, Prithviraj Bose, Jason Gotlib, Peter Valent, Chih-Cheng Chen, Tiziano Barbui, Raajit Rampal, Srdan Verstovsek, Steffen Koschmieder, Giuseppe Saglio, Richard A Van Etten
The 60th American Society of Hematology (ASH) held in San Diego in December 2018 was followed by the 13th Post-ASH chronic myeloproliferative neoplasms (MPNs) workshop on the 4th -5th December 2018. This closed annual workshop, first introduced in 2006 by Goldman and Mughal, was organized in collaboration with Alpine Oncology Foundation and allowed experts in preclinical and clinical research in the chronic MPNs to discuss the current scenario, including relevant presentations at ASH, and address pivotal open questions that impact translational research and clinical management...
April 23, 2019: Hematological Oncology
https://read.qxmd.com/read/30991463/mina53-regulates-the-differentiation-and-proliferation-of-leukemia-cells
#9
LETTER
Lixiao Zhou, Ting Zhang, Qiang Zhu, Pengcheng Zhang, Liyang Yu, Binghui Shen, Wen Yi, Mengsheng Qiu, Chenggang Zhu
No abstract text is available yet for this article.
April 16, 2019: Hematological Oncology
https://read.qxmd.com/read/30990910/human-telomerase-reverse-transcriptase-expression-in-a-cd34-positive-hematopoietic-progenitor-of-myelodysplastic-syndrome-and-acute-myelogenous-leukemia
#10
LETTER
Hiroshi Handa, Natsumi Nishimoto, Madoka Inoue, Akihiko Yokohama, Norifumi Tsukamoto, Takayuki Saitoh, Hirokazu Murakami
No abstract text is available yet for this article.
April 16, 2019: Hematological Oncology
https://read.qxmd.com/read/30985017/impact-of-2016-who-diagnosis-of-early-and-overt-primary-myelofibrosis-on-presentation-and-outcome-of-232-patients-treated-with-ruxolitinib
#11
LETTER
Francesca Palandri, Giuseppe A Palumbo, Elisabetta Abruzzese, Alessandra Iurlo, Nicola Polverelli, Elena Elli, Massimiliano Bonifacio, Micaela Bergamaschi, Bruno Martino, Mario Tiribelli, Giulia Benevolo, Alessia Tieghi, Nicola Sgherza, Alessandro Isidori, Gianni Binotto, Monica Crugnola, Florian Heidel, Francesco Cavazzini, Costanza Bosi, Giuseppe Auteri, Daniele Cattaneo, Robin Foà, Roberto M Lemoli, Antonio Cuneo, Mauro Krampera, Daniela Bartoletti, Michele Cavo, Nicola Vianelli, Massimo Breccia, Roberto Latagliata
2016-WHO criteria identified early-Primary Myelofibrosis as an individual entity with milder clinical features and better outcome compared to overt-PMF. Here, we compared early and overt-PMF patients treated with ruxolitinib in terms of baseline clinical/laboratory characteristics, response and toxicity to treatment. We observed that early-PMF patients achieve better and more stable spleen and symptoms responses, with significantly lower rates of haematological toxicities. No differences in overall and leukemia-free survival were detected between the two cohorts...
April 15, 2019: Hematological Oncology
https://read.qxmd.com/read/30983008/a-multi-center-retrospective-comparison-of-induction-chemoimmunotherapy-regimens-on-outcomes-in-transplant-eligible-patients-with-previously-untreated-mantle-cell-lymphoma
#12
Zi Yun Ng, Mark Bishton, David Ritchie, Robert Campbell, Michael Gilbertson, Kate Hill, Sumita Ratnasingam, Anthony Schwarer, Kate Manos, Sophie Shorten, Melissa Ng, Niles Nelson, Liu Xin, Sanjay De Mel Widanalage, Tenny Sunny, Duncan Purtill, Michelle Poon, Anna Johnston, Tara Cochrane, Hui-Peng Lee, Greg Hapgood, Constantine Tam, Stephen Opat, Eliza Hawkes, John Seymour, Chan Yoon Cheah
Mantle cell lymphoma (MCL) is an uncommon and typically aggressive form of lymphoma. Although often initially chemosensitive, relapse is common. Several induction and conditioning regimens are used in transplant eligible patients and the optimal approach remains unknown. We performed an international, retrospective study of transplant eligible patients to assess impact of induction chemo-immunotherapy and conditioning regimens on clinical outcomes. We identified 228 patients meeting inclusion criteria. Baseline characteristics were similar among the induction groups except for some variation in age...
April 15, 2019: Hematological Oncology
https://read.qxmd.com/read/30950076/smoking-influences-the-outcomes-of-patients-receiving-tyrosine-kinase-inhibitors-for-chronic-myeloid-leukemia-in-the-chronic-phase-a-retrospective-analysis
#13
LETTER
Noriyoshi Iriyama, Michihide Tokuhira, Eriko Sato, Kei-Ji Sugimoto, Tomoiku Takaku, Maho Ishikawa, Tomonori Nakazato, Hiroyuki Fujita, Yuta Kimura, Isao Fujioka, Norio Asou, Norio Komatsu, Masahiro Kizaki, Yoshihiro Hatta, Tatsuya Kawaguchi
No abstract text is available yet for this article.
April 4, 2019: Hematological Oncology
https://read.qxmd.com/read/30945323/identification-of-a-novel-trna-derived-rna-fragment-exhibiting-high-prognostic-potential-in-chronic-lymphocytic-leukemia
#14
Paraskevi Karousi, Katerina Katsaraki, Sotirios G Papageorgiou, Vasiliki Pappa, Andreas Scorilas, Christos K Kontos
tRNA-derived fragments (tRFs) are 16-28 nucleotide fragments, which occur by specific cleavage of tRNA molecules. i-tRF-GlyGCC is an internal tRF, originating from the tRNAs bearing the Glycine anticodon "GCC". Other tRFs generated from tRNAGlyGCC have proved to be associated with various cancer types. Chronic lymphocytic leukemia (CLL) is a type of leukemia during which CD5+ B lymphocytes accumulate in marrow and lymphoid tissues and is characterized by differential clinical features among patients...
April 4, 2019: Hematological Oncology
https://read.qxmd.com/read/30938858/induction-therapy-in-acute-myeloid-leukemia-is-it-time-to-put-aside-standard-3-7
#15
REVIEW
Felicetto Ferrara, Orsola Vitagliano
For more than 30 years after its introduction, the combination of an anthracycline, usually daunorubicin, given for 3 days with continuous infusion of cytarabine for 7 days (3 + 7) has been the standard induction regimen for patients with acute myeloid leukemia (AML). In the last decade, there has been a progressive understanding of the molecular pathogenesis of the disease, which has led to discovery of potential therapeutic targets, resulting in selective treatment approaches aimed at rational and personalized treatment strategies...
April 2, 2019: Hematological Oncology
https://read.qxmd.com/read/30938848/front-line-treatment-of-diffuse-large-b-cell-lymphoma-beyond-r-chop
#16
REVIEW
Patrizia Mondello, Michael Mian
Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured with the standard immunochemotherapy R-CHOP, one-third of them relapses with a dismal outcome in most cases. In the recent years remarkable advances have been achieved based on the discovery of molecular genetics in DLBCL. In addition to the major cell-of-origin designations of germinal center B-cell and activated B-cell subtypes, next-generation sequencing has unveiled the remarkable complexity of DLBCL and identified potential molecular targets for tailored therapies...
April 2, 2019: Hematological Oncology
https://read.qxmd.com/read/30938836/patients-assigned-to-vgpr-pr-and-sd-in-the-imwg-response-category-are-composed-of-heterogeneous-population-when-assessed-by-the-heavy-light-chain-assay
#17
LETTER
Yoshikazu Kamiya, Takaaki Chou, Hirokazu Murakami, Hiroshi Handa, Shuji Ozaki, Chihiro Shimazaki, Shin-Ichi Fuchida, Jun Okada, Junji Itoh, Satoru Sugiyama, Kazuyuki Shimizu
No abstract text is available yet for this article.
April 2, 2019: Hematological Oncology
https://read.qxmd.com/read/30933368/metabolic-tumour-volume-and-response-to-therapy-in-diffuse-large-b-cell-lymphoma
#18
LETTER
Leonardo Campiotti, Matteo B Suter, Diego De Palma, Ilaria Proserpio, Silvia Uccella, Alessandro Squizzato
No abstract text is available yet for this article.
April 1, 2019: Hematological Oncology
https://read.qxmd.com/read/30933366/relative-dose-intensity-of-r-chop-therapy-and-patient-outcomes-in-advanced-follicular-lymphoma
#19
LETTER
Tatsuya Konishi, Yusuke Kanemasa, Yuki Sasaki, Toshihiro Okuya, Tsukasa Yamaguchi, Chikako Funasaka, Tatsu Shimoyama, Yasushi Omuro
No abstract text is available yet for this article.
April 1, 2019: Hematological Oncology
https://read.qxmd.com/read/30924173/rna-seq-analyses-demonstrate-evi-1-induced-morbid-hematopoiesis-and-developmental-abnormality-in-zebrafish-were-related-with-mapk-pathway
#20
LETTER
Wenjing Lang, Jiayi Cai, Fangyuan Chen, Jianyi Zhu, Xiaoli Hu, Jihua Zhong
No abstract text is available yet for this article.
March 28, 2019: Hematological Oncology
journal
journal
28626
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"